文献速递血管炎

血管紧张素受体阻滞与巨细胞动脉炎风险增加相关

Angiotensin receptor blockade is associated with increased risk of giant cell arteritis.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

该匹配队列研究纳入1995至2019年英国初级保健数据中超过100万例新启用降压药的成人,比较血管紧张素受体阻滞剂(ARB)、血管紧张素转换酶抑制剂(ACEi)及其他降压药启动者的巨细胞动脉炎(GCA)发生风险。ARB启动者GCA风险高于ACEi启动者(HR 1.55;95%CI 1.16,2.06),其他降压药与ACEi之间无显著差异(HR 1.08;95%CI 0.87,1.35)。

要点

  • ARB启动者GCA风险高于ACEi启动者(HR 1.55;95%CI 1.16,2.06)。
  • 其他降压药启动者与ACEi启动者GCA风险无显著差异(HR 1.08;95%CI 0.87,1.35)。
  • ARB组GCA发病率为每10000患者年2.73(95%CI 2.12,3.50)。

核心结论

  • 与ACEi或其他降压药相比,启动ARB与GCA风险升高相关。
  • 作者指出,血管紧张素受体生物学的机制研究将为进一步理解该发现提供清晰度。

研究设计与样本

  • 匹配队列研究,纳入1995至2019年英国初级保健数据中启动降压药的成人。
  • 未接受过治疗且无既往GCA或风湿性多肌痛的个体分为三组:ARB启动者、ACEi启动者、其他降压药启动者(β受体阻滞剂、钙通道阻滞剂、利尿剂或α肾上腺素受体阻滞剂)。
  • 随访至多5年,采用逆概率加权Cox模型建模结局风险,并调整生活方式参数、合并症和合并用药。

主要发现

  • 共纳入超过100万例新启用降压药者,其中ARB 81780例、ACEi 422940例、其他降压药873066例。
  • 每10000患者年GCA发病率:ARB组2.73(95%CI 2.12,3.50),ACEi组1.76(95%CI 1.25,2.39),其他降压药组1.90(95%CI 1.37,2.56)。
  • ARB启动者GCA风险高于ACEi启动者(HR 1.55;95%CI 1.16,2.06)。
  • 其他降压药启动者与ACEi启动者之间GCA风险相似(HR 1.08;95%CI 0.87,1.35)。

关键数值与推荐

  • GCA事件定义采用经验证的Read编码,要求发病年龄≥50岁且至少2次糖皮质激素处方。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Angiotensin II is implicated in GCA pathology. We examined whether the use of angiotensin receptor blockers (ARBs) is associated with GCA risk compared with angiotensin-converting enzyme inhibitors (ACEis) or other antihypertensives. METHODS: We performed a matched cohort study including adults who were initiators of antihypertensives in UK primary care data between 1995 and 2019. Treatment-naïve individuals without prior GCA or PMR were categorized into three groups-ARB initiators, ACEi initiators, or other antihypertensive initiators (beta-blockers, calcium channel blockers, diuretics or alpha-adrenoceptor blockers)-and followed for up to 5 years. Incident GCA was defined using validated Read codes, with age of onset ≥50 years and two or more glucocorticoid prescriptions. Inverse probability-weighted Cox models were used to model outcome risk, adjusting for lifestyle parameters, comorbidities and comedications. RESULTS: Among >1 million new starters of antihypertensives (81 780 ARBs, 422 940 ACEis and 873 066 other antihypertensives), the incidence rate of GCA per 10 000 patient-years was 2.73 (95% CI 2.12, 3.50) in the ARB group, 1.76 (95% CI 1.25, 2.39) in the ACEi group and 1.90 (95% CI 1.37, 2.56) in the other antihypertensives group. The hazard of GCA was higher in ARB initiators [hazard ratio (HR) 1.55; 95% CI 1.16, 2.06] than initiators of ACEis, but similar between initiators of other antihypertensives and ACEis (HR 1.08; 95% CI 0.87, 1.35). CONCLUSIONS: Initiation of ARBs is associated with a higher risk of GCA compared with ACEis or other antihypertensives. Mechanistic studies of angiotensin receptor biology will provide further clarity for our findings.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Zhao SS, Lyu H, Zeng C, et al. Angiotensin receptor blockade is associated with increased risk of giant cell arteritis. Rheumatology (Oxford). 2023. PMID: 36255257. doi:10.1093/rheumatology/keac599

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。